Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate ...
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 ...
16h
Sunlands Technology Group Announces Unaudited Fourth Quarter and Full Year 2025 Financial Results
Sunlands Technology Group (NYSE: STG) (“Sunlands” or the “Company”), a leader in China’s adult online education market and China’s adult personal interest learning market, today announced its ...
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of ...
Intelligent Protection Management Corp. (NASDAQ:IPM) Q4 2025 Earnings Call Transcript March 17, 2026 Intelligent Protection Management Corp. misses on earnings expectations. Reported EPS is $-0.05 EPS ...
Indian-origin Adobe CEO Shantanu Narayen plans to step down after 18 years. Explore his career trajectory, Hyderabad roots, ...
Aclarion, Inc., ('Aclarion” or the 'Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is ...
NEW CANAAN, CT / ACCESS Newswire / March 13, 2026 / Network‑1 Technologies, Inc. (NYSE American:NTIP) ("Network‑1"), a ...
Detailed price information for Vox Royalty Corp (VOXR-T) from The Globe and Mail including charting and trades.
Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful ...
Operator: Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on investigator-initiated exploratory studies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results